Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(146 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(169 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(87 products)
- Src(79 products)
- Syk(37 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1430 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
FGFR-IN-5
CAS:<p>FGFR-IN-5 is a potent inhibitor of FGFR. FGFR-IN-5 has potential for research in cancer diseases.</p>Formula:C25H22N6O3Color and Shape:SolidMolecular weight:454.48EGFR-IN-35
CAS:<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96I194496
CAS:<p>I194496 is an effective inhibitor of cystathionine γ-lyase (CSE) with an IC50 value of 0.79 mM. It inhibits the growth of human TNBC cells by dual targeting the PI3K/Akt and Ras/Raf/ERK pathways. Additionally, I194496 suppresses the metastasis of human TNBC cells by downregulating the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.</p>Formula:C28H23F2N5O5SColor and Shape:SolidMolecular weight:579.58VEGFR-2-IN-12
<p>VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.</p>Formula:C22H24N6O3SColor and Shape:SolidMolecular weight:452.53EGFR-IN-45
<p>EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.</p>Formula:C28H23N7OColor and Shape:SolidMolecular weight:473.53SYHA1815
CAS:SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.Formula:C27H26ClF4N5OColor and Shape:SolidMolecular weight:547.98FLT3/TrKA-IN-1
<p>FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.</p>Formula:C28H30N4O2Color and Shape:SolidMolecular weight:454.56DDO-02267
CAS:<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formula:C18H12N2O7SColor and Shape:SolidMolecular weight:400.362CLM3
CAS:<p>CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.</p>Formula:C21H21N5Color and Shape:SolidMolecular weight:343.43EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Formula:C16H16N4O2SColor and Shape:SolidMolecular weight:328.39VEGFR-2-IN-25
CAS:<p>VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).</p>Formula:C24H22N6O2Color and Shape:SolidMolecular weight:426.47Multi-kinase inhibitor 3
CAS:<p>Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.</p>Formula:C26H26N6O2Color and Shape:SolidMolecular weight:454.52LT-850-166
<p>LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.</p>Formula:C30H29Cl2N7OColor and Shape:SolidMolecular weight:574.5Sacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Formula:C32H31ClN6O4Color and Shape:SolidMolecular weight:599.08EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formula:C26H27ClN6O2Color and Shape:SolidMolecular weight:490.98SILA-123
CAS:<p>SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0/G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.</p>Formula:C24H25N5O2Color and Shape:SolidMolecular weight:415.49HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Formula:C26H32N8O3Color and Shape:SolidMolecular weight:504.58EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formula:C30H35FN6O3Color and Shape:SolidMolecular weight:546.64BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Formula:C30H32N6O4Color and Shape:SolidMolecular weight:540.61HER2-IN-7
CAS:<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formula:C28H26F3N7O3Color and Shape:SolidMolecular weight:565.55
